---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-225323"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-05-15T11:35:06+00:00"
generated_at: "2026-05-15T11:40:46.573745+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Q1 net loss $170.2M; cash $202.8M; PIKTOR trial advances

## Summary
- Net loss of $170.2M ($131.45 per share) vs $6.9M loss a year ago, driven by $133.0M acquired IPR&D charge from Faeth acquisition.
- Cash, cash equivalents and marketable securities $202.8M, up from $21.2M at Dec 31, 2025, after $200M private placement in February.
- First patient dosed in Phase 1b/2 trial of PIKTOR for HR+/HER2- advanced breast cancer; Phase 2 endometrial cancer topline data expected H2 2026.
- R&D expenses $18.0M (vs $3.7M) and G&A $19.7M (vs $3.5M) both increased due to Faeth acquisition and one-time costs.

## SEC filing metadata
- accession: 0001193125-26-225323
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-05-15T11:35:06+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/0001193125-26-225323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/d125741d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-225323
- JSON: https://secwatch.observer/filing/0001193125-26-225323.json
- Plain text: https://secwatch.observer/filing/0001193125-26-225323.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $170.2 million, or $131.45 per basic and diluted share.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss was $170.2 million, or $131.45 per basic and diluted share
  - Result: reported results
  source text: On May 15, 2026, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/0001193125-26-225323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.